BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/14/2024 5:31:16 PM | Browse: 125 | Download: 307
 |
Received |
|
2023-12-23 03:00 |
|
Peer-Review Started |
|
2023-12-23 03:00 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2024-01-13 07:52 |
|
Revised |
|
2024-01-22 14:19 |
|
Second Decision |
|
2024-02-21 02:45 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2024-02-21 05:49 |
|
Articles in Press |
|
2024-02-21 05:49 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-03-04 09:21 |
|
Publish the Manuscript Online |
|
2024-03-14 17:31 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Editorial |
| Article Title |
Vonoprazan-amoxicillin dual regimen with Saccharomyces boulardii as a rescue therapy for Helicobacter pylori: Current perspectives and implications
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Valerie Josephine Dirjayanto, Jessica Audrey and Daniel Martin Simadibrata |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Daniel Martin Simadibrata, MD, MSc, Postdoctoral Fellow, Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First St. SW, Rochester, Minnesota 55905, United States. simadibrata.daniel@mayo.edu |
| Key Words |
Vonoprazan; Saccharomyces boulardii; Helicobacter pylori; Rescue therapy; Eradication rate |
| Core Tip |
Vonoprazan-amoxicillin dual therapy with Saccharomyces boulardii (S. boulardii, VAS regimen) emerges as a novel rescue therapy for eradicating Helicobacter pylori (H. pylori). Vonoprazan, a potassium-competitive acid blocker, exhibits superior acid suppression compared to proton pump inhibitors. Notably, dual therapy minimizes the use of an additional antibiotic while maintaining efficacy comparable to traditional triple therapy. This paper highlights the role of S. boulardii, a probiotic, in enhancing the efficacy of Vonoprazan dual therapy by restoring gut microbiota balance, directly affecting H. pylori, and regulating immunomodulation. The VAS regimen emerges as a promising treatment alternative, demonstrating remarkable eradication of H. pylori, even in triple-resistant strains. |
| Publish Date |
2024-03-14 17:31 |
| Citation |
Dirjayanto VJ, Audrey J, Simadibrata DM. Vonoprazan-amoxicillin dual regimen with Saccharomyces boulardii as a rescue therapy for Helicobacter pylori: Current perspectives and implications. World J Gastroenterol 2024; 30(10): 1280-1286 |
| URL |
https://www.wjgnet.com/1007-9327/full/v30/i10/1280.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v30.i10.1280 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
